Using a novel SARS-Cov-2-specific artificial antigen presenting cell, coupled with a rapid expansion protocol as practiced in tumor infiltrating lymphocytes therapy, researchers generated an immune catalytic quantity of VIL.
[Scientific Reports]
6445218
{6445218:8Q9KPNVS}
apa
50
1
165081
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/